Davis DP, Graydon C, Stein R, et al. The positive predictive value of paramedic versus emergency physician interpretation of the prehospital 12‐lead electrocardiogram. Prehosp Emerg Care. 2007; 11:399–402.
26 26 Kontos MC, Gunderson MR, Zegre‐Hemsey JK, et al. Prehospital activation of hospital resources (preact) ST‐segment‐elevation myocardial infarction (STEMI): a standardized approach to prehospital activation and direct to the catheterization laboratory for STEMI recommendations from the American Heart Association's mission: Lifeline Program. J Am Heart Assoc. 2020; 9:e011963.
27 27 Wang K, Asinger RW, Marriott HJ. ST‐segment elevation in conditions other than acute myocardial infarction. N Engl J Med. 2003; 349:2128–35.
28 28 Stub D, Smith K, Bernard S, et al. Air versus oxygen in ST‐segment‐elevation myocardial infarction. Circulation. 2015; 131:2143–50.
29 29 ISIS‐2 investigators. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS‐2. ISIS‐2 (Second International Study of Infarct Survival) Collaborative Group. Lancet. 1988; 2:349–60.
30 30 Quan D, LoVecchio F, Clark B, Gallagher JV, 3rd. Prehospital use of aspirin rarely is associated with adverse events. Prehosp Disaster Med. 2004; 19:362–5.
31 31 Barbash I, Freimark D, Gottlieb S, et al. Outcome of myocardial infarction in patients treated with aspirin is enhanced by pre‐hospital administration. Cardiology. 2002; 98:141–7.
32 32 Freimark D, Matetzky S, Leor J, et al. Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis. Am J Cardiol. 2002; 89:381–5.
33 33 Lewis JF, Zeger SL, Li X, et al. Gender differences in the quality of EMS care nationwide for chest pain and out‐of‐hospital cardiac arrest. Womens Health Issues. 2019; 29:116–24.
34 34 Tataris KL, Mercer MP, Govindarajan P. Prehospital aspirin administration for acute coronary syndrome (ACS) in the USA: an EMS quality assessment using the NEMSIS 2011 database. Emerg Med J. 2015; 32:876–81.
35 35 GISSI‐3 Investigators. GISSI‐3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6‐week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet. 1994; 343:1115–22.
36 36 Henrikson CA, Howell EE, Bush DE, et al. Chest pain relief by nitroglycerin does not predict active coronary artery disease. Ann Intern Med. 2003; 139:979–86.
37 37 Robichaud L, Ross D, Proulx MH, et al. Prehospital nitroglycerin safety in inferior ST elevation myocardial infarction. Prehosp Emerg Care. 2016; 20:76–81.
38 38 Proulx MH, de Montigny L, Ross D, Vacon C, Juste LE, Segal E. Prehospital nitroglycerin in tachycardic chest pain patients: a risk for hypotension or not? Prehosp Emerg Care. 2017; 21(1):68–73.
39 39 Meine TJ, Roe MT, Chen AY, et al. Association of intravenous morphine use and outcomes in acute coronary syndromes: results from the CRUSADE Quality Improvement Initiative. Am Heart J. 2005; 149(6):1043–9.
40 40 Koh JQS, Fernando H, Peter K, Stub D. Opioids and ST elevation myocardial infarction: a systematic review. Heart Lung Circ. 2019; 28:697–706.
41 41 Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients with ST‐Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients with ST‐Elevation Myocardial Infarction, writing on behalf of the 2004 Writing Committee. Circulation. 2008; 117:296–329.
42 42 Weldon ER, Ariano RE, Grierson RA. Comparison of fentanyl and morphine in the prehospital treatment of ischemic type chest pain. Prehosp Emerg Care. 2016; 20(1):45–51.
43 43 Chen ZM, Pan HC, Chen YP, et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lance. 2005; 366(9497):1622–32.
44 44 Weaver WD, Cerqueira M, Hallstrom AP, et al. Prehospital‐initiated vs hospital‐initiated thrombolytic therapy. The Myocardial Infarction Triage and Intervention Trial. JAMA. 1993; 270:1211–6.
45 45 The European Myocardial Infarction Project Group. Prehospital thrombolytic therapy in patients with suspected acute myocardial infarction. N Engl J Med. 1993; 329:383–9.
46 46 Morrison LJ, Verbeek PR, McDonald AC, Sawadsky BV, Cook DJ. Mortality and prehospital thrombolysis for acute myocardial infarction: a meta‐analysis. JAMA. 2000; 283:2686–92.
47 47 Savino PB, Sporer KA, Barger JA, et al. Chest pain of suspected cardiac origin: current evidence‐based recommendations for prehospital care. West J Emerg Med. 2015; 16:983–95.
48 48 Stenestrand U, Lindback J, Wallentin L. Long‐term outcome of primary percutaneous coronary intervention vs prehospital and in‐hospital thrombolysis for patients with ST‐elevation myocardial infarction. JAMA. 2006; 296:1749–56.
49 49 Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial‐‐PRAGUE‐2. Eur Heart J. 2003; 24:94–104.
50 50 Busk M, Maeng M, Rasmussen K, et al. The Danish multicentre randomized study of fibrinolytic therapy vs. primary angioplasty in acute myocardial infarction (the DANAMI‐2 trial): outcome after 3 years follow‐up. Eur Heart J. 2008; 29:1259–66.
51 51 Swor R, Anderson W, Jackson R, Wilson A. Effects of EMS transportation on time to diagnosis and treatment of acute myocardial infarction in the emergency department. Prehosp Disaster Med. 1994; 9:160–4.
52 52 Luepker RV, Raczynski JM, Osganian S, et al. Effect of a community intervention on patient delay and emergency medical service use in acute coronary heart disease: The Rapid Early Action for Coronary Treatment (REACT) Trial. JAMA. 2000; 284:60–7.
53 53 McNamara RL, Wang Y, Herrin J, et al. Effect of door‐to‐balloon time on mortality in patients with ST‐segment elevation myocardial infarction. J Am Coll Cardiol. 2006; 47:2180–6.
54 54 Brown JP, Mahmud E, Dunford JV, Ben‐Yehuda O. Effect of prehospital 12‐lead electrocardiogram on activation of the cardiac catheterization laboratory and door‐to‐balloon time in ST‐segment elevation acute myocardial infarction. Am J Cardiol. 2008; 101:158–61.
55 55 Bradley EH, Herrin J, Wang Y, et al. Strategies for reducing the door‐to‐balloon time in acute myocardial infarction. N Engl J Med. 2006; 355:2308–20.
56 56 Larson DM, Menssen KM, Sharkey SW, et al. “False‐positive” cardiac catheterization laboratory activation among patients with suspected ST‐segment elevation myocardial infarction. JAMA. 2007; 298:2754–60.
57 57 Youngquist ST, Kaji AH, Lipsky AM, Koenig WJ, Niemann JT. A Bayesian sensitivity analysis of out‐of‐hospital 12‐lead electrocardiograms: implications for regionalization of cardiac care. Acad Emerg Med. 2007; 14:1165–71.
58 58 Nestler DM, White RD, Rihal CS, et al. Impact of prehospital electrocardiogram protocol and immediate catheterization team activation for patients with ST‐elevation‐myocardial infarction. Circ Cardiovasc Qual Outcomes. 2011; 4:640–6.
59 59 Cone DC, Lee CH, Van Gelder C. EMS activation of the cardiac catheterization laboratory is associated with process improvements in the care of myocardial infarction patients. Prehosp Emerg Care. 2013; 17:293–8.
60 60 Horvath SA, Xu K, Nwanyanwu F, et al. Impact of the prehospital activation strategy in patients with ST‐elevation myocardial infarction undergoing primary percutaneous revascularization: a single center community hospital experience. Crit Pathw Cardiol. 2012; 11:186–92.
61 61 Shavadia